Search

Search Constraints

You searched for: Author/Creator Mileshkin, Linda

Search Results

1. 2022-RA-568-ESGO Prognostic Relevance of FIGO grading is Limited to NSMP Endometrial Cancers. (20th October 2022)

2. 2022-RA-648-ESGO Interpretable deep learning provides clues for prognostic refinement of the molecular endometrial cancer classification. (20th October 2022)

3. 2022-RA-925-ESGO Development of adjuvant treatment decision support tool for endometrial cancer patients by pooled analysis of data from 2000 women included in the PORTEC-1–3 trials and a prospective cohort study. (20th October 2022)

4. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. (25th March 2021)

5. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary. Issue 1 (30th November 2022)

6. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Issue 3 (March 2018)

7. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Issue 9 (September 2019)

8. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Issue 9 (September 2019)

9. Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. Issue 1 (1st January 2016)

10. Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. Issue 1 (January 2016)